Drugmakers, Consumers Help Danish Economy to Extend Rebound
Denmark’s economy extended gains in the third quarter as drugmakers continued to grow their output while domestic demand also ...
RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health ...
Daily1h
Novo Nordisk Enters China's Obesity Market with Wegovy Launch, Eyes 180 Million Patients
The move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has ...
Narrow-Moat Catalent's Acquisition by Novo Nordisk Remains on Track; Boosting Wegovy Manufacturing
Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...
A Staggering Number of U.S. Adults Are Eligible for Ozempic, Study Finds
A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.
Becker's Hospital Review11h
Eli Lilly, Novo Nordisk urge employers to cover cost of weight loss drugs
Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.
How RFK Jr.'s war on obesity in the age of Ozempic could shake up the booming weight-loss industry
Kennedy has promised to "Make America Healthy Again" by tackling obesity with nutrition. Here's how he could rattle the ...
JD Supra14h
Novo Nordisk Pushes for FDA Listing of Semaglutide Products
On October 22, Novo Nordisk (Novo) nominated semaglutide products, which include its popular drugs marketed as Ozempic for type 2 diabetes and ...
AHA 2024: semaglutide continues to impress in diabetic kidney disease
KOLs interviewed by GlobalData think that semaglutide can be a treatment option for non-diabetic CKD patients whose kidney ...
More than half of U.S. adults might be candidates for Ozempic
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...
Healthcare Executives Expect More IPOs and Corporate Dealmaking in 2025
FRANKFURT (Reuters) - Healthcare executives and investors expect an uptick in initial public offerings and corporate ...
How Long Is It Safe to Stay on Ozempic?
There’s no hard-and-fast rule for how long it’s safe to stay on Ozempic for weight loss. Novo Nordisk-sponsored studies lasting up to two years show that semaglutide is safe.